Publications

For most recent updates check here.

A selection of important publications:

  • Zegers CM, Hoebers FJ, van Elmpt W, Bons JA, Öllers MC2, Troost EG, Eekers D, et.al;
    Evaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer.  Eur J Nucl Med Mol Imaging 2016.. DOI 10.1007/s00259-016-3429-y
  • De Ruyck K, Duprez F, Ferdinande L. et al;
    A let-7 microRNA polymorphism in the KRAS 3’-UTR is prognostic in oropharyngeal cancer. Cancer Epidemiology 2014, 38: 591-598
  • Fox NS, Starmans MHW, Haider S et al;
    Ensemble analyses improve signatures of tumour hypoxia and reveal inter-platorm differences.
    BMC Bioinformatics 2014, 15: 170. Doi:10.1186/1471-2105-15-170
  • Parmar C, Rios Velazquez E, Leijenaar R et al;
    Robust radiomics feature quantification using semiautomatic volumetric segmentation.
    PLoS ONE (2014); 9(7): e102107. Doi:1-.1371/journal.pone.0102107
  • Aerts HJWL, Rios Velazquez, Leijenaar RTH et al;
    Decoding tumour phenotype by noninvastive imaging using a quantitative radiomics approach.

    Nature Communications (2014); Doi:10.1038/ncomms5006
  • Van Elmpt W, Öllers M, Dingemans AMC, Lambin P, De Ruysscher D.
    Response assessment using 18F-FDG PET early in the course of radiotherapy correlated with survival in advanced stage non-small cell lung cancer.
    J Nucl Med 2012; 53:1514-1520
  • Van Elmpt W, De Ruysscher D, Van der Salm A, Lakeman A, Van der Stoep J, Emans D, Damen E, Öllers M, Sonke JJ, Belderbos J.
    The PET-boost randomized phase II dose-escalation trial in non-small cell lung cancer.
    Radiother Oncol 2012; 104:67-71
  • Heukelom J, Hamming O, Bartelink H, Hoebers F, Giralt J, Herlestam T, Verheij M, van den Brekel M, Vogel W, Slevin N, Deutsch E, Sonke JJ, Lambin P, Rasch C.
    Adaptive and innovative radiation treatment for improving cancer treatment outcome (ARTFORCE): a randomized controlled phase II trial for individualized treatment of head and neck cancer.
    BMC Cancer 2013. ePub. PMID: 23433435, 2013. http://www.biomedcentral.com/1471-2407/13/84
  • Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.
    Trial Watch: adoptive cell transfer for anticancer immunotherapy.
    Oncoimmunology 2013; 2(5): e24238
  • Vacchelli E, Eggermont A, Fridman WH, Galon J, Zirvogel L, Kroemer G, Galluzzi L..
    Trial Watch: Immunostimulatory cytokines.
    Oncoimmunology 2013 2(7) e24850, Epub 2013 May 7.
  • Galluzzi, L., Goubar, A., Olaussen, K. A., Vitale, I., Senovilla, L., Michels, J., et al.
    Prognostic value of LIPC in non-small cell lung carcinoma.
    Cell Cycle 2013, 12, 647-654.
  • Galluzzi, L., Marsili, S., Vitale, I., Senovilla, L., Michels, J., Garcia, P., et al.
    Vitamin B6 metabolism influences the intracellular accumulation of cisplatin.
    Cell Cycle 2013; 12: 417-421.
  • Galluzzi, L., Vacchelli, E., Michels, J., Garcia, P., Kepp, O., Senovilla, L., et al.
    Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses.
    Oncogene 2013; 32: 4995-5004.
  • Yao, Z., Jones, A. W., Fassone, E., Sweeney, M. G., Lebiedzinska, M., Suski, J. M., et al. (2013).
    PGC-1beta mediates adaptive chemoresistance associated with mitochondrial DNA mutations.
    Oncogene 2013; 32: 2592-2600.
  • Michels J, Vitale I, Galluzzi L. et al.
    Cisplatin Resistance Associated with PARP hyperactivation.
    Cancer Res 2013; 73: 2271-2280